ME Jan 2025 3.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:42AM EDT. Market open.
Loading interactive chart…
- Simply Wall St.
23andMe Holding Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
23andMe Holding ( NASDAQ:ME ) Full Year 2024 Results Key Financial Results Revenue: US$219.6m (down 27% from FY 2023...
- Thomson Reuters StreetEvents
Q4 2024 23andMe Holding Co. Earnings Call
Q4 2024 23andMe Holding Co. Earnings Call
- GlobeNewswire
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024 (FY24), which ended March 31, 2024. Key Results and Recent Developments On March 28, 2024 the Board of Directors of 23andMe formed a Special Committee comprised of independent directors to review strategic alternatives that may be available to 23andMe to maxim
© 2024 Yahoo. All rights reserved.